Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in patients with BPSD

Version 1 : Received: 6 January 2022 / Approved: 10 January 2022 / Online: 10 January 2022 (11:19:35 CET)

How to cite: Qasim, H. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in patients with BPSD. Preprints 2022, 2022010099 (doi: 10.20944/preprints202201.0099.v1). Qasim, H. Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in patients with BPSD. Preprints 2022, 2022010099 (doi: 10.20944/preprints202201.0099.v1).

Abstract

Background: The psychomotor agitation of the behavioural and psychological symptoms of dementia (BPSD) is one of the common issues in aged care facilities, leading to the poor functional and medical consequences. Psychotropic interventions are the preferred choice of treatment, but which medication should be the prescribers first preference? This review aims to compare pharmacological interventions for psychomotor agitation, judging them according to their effectuality and justifiability profiles. This is to be achieved by retrieving information from Randomised Control Trials (RCTs) and systematic reviews. Objectives: This review evaluates evidence from RCTs, systematic reviews, and meta-analyses of BPSD patients who have taken agitation treatments. Assessing the efficacy of selective serotonin reuptake inhibitors (SSRI) and antipsychotic treatments when compared to each other for the purpose of improving agitation outcomes. Methods: This review includes RCT that compared one or more active ingredient medications with another medication or with a placebo, along with systematic reviews comparing citalopram (SSRI) with antipsychotics such as quetiapine, olanzapine, and risperidone. Studies were extracted by searching and accessing databases, such as PubMed, OVID, and Cochrane with restrictions of date from 2000 to 2021 and English language. Conclusion: There is still limited studies of SSRIs for the treatment of agitation in BPSD. SSRIs such as citalopram were associated with a reduction in symptoms of agitation, and lower risk of adverse effects compared to antipsychotics. Future studies are required to assess the long-term safety and efficacy of SSRI treatments for agitation in BPSD.

Keywords

BPSD; antipsychotics; SSRIs; dementia; agitation

Subject

MEDICINE & PHARMACOLOGY, Behavioral Neuroscience

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.